Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 3/20 | 0.40 |
| ▸ | CDK9 | P50750 | 3/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6951707 | 0.87 | CCNT1 (0.46) | CCNT1CDK9CDK2CCNA2 | |
| SCHEMBL6952810 | 0.82 | CCNT1 (0.37) | CCNT1CDK9SIRT2CDK2CCNA2 | |
| SCHEMBL6956467 | 0.82 | ASAH1 (0.40) | CCNT1CDK9CDK2CCNA2 | |
| SCHEMBL7500940 | 0.80 | CCNT1 (0.46) | CCNT1CDK9CDK2CCNA2 | |
| SCHEMBL6952834 | 0.79 | CCNT1 (0.52) | CCNT1CDK9CDK2CCNA2 | |
| SCHEMBL7501550 | 0.79 | CCNT1 (0.49) | CCNT1CDK9CDK2CCNA2 | |
| SCHEMBL6956384 | 0.79 | CCNT1 (0.46) | CCNT1CDK9CDK2CCNA2 | |
| Phosphoric Acid SCHEMBL6951263 | 0.79 | CCNT1 (0.47) | CCNT1CDK9CDK2CCNA2 | |
| SCHEMBL27463188 | 0.79 | CCNT1 (0.40) | CCNT1CDK9CDK2CCNA2 | |
| SCHEMBL7651446 | 0.79 | CCNE2 (0.47) | CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224181-B1 | SUBSTITUTED PYRROLES AS ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2003-12-03 | — | — | EP | disclosed |
| US-6559164-B1 | These compounds and their pharmaceutically acceptable salts are suitable for administration to patients as continuous infusion solution and are useful in the treatment and/or control of cell proliferative disorders, in particular cancer. | HOFFMANN-LA ROCHE INC. | 2003-05-06 | — | — | US | disclosed |
| EP-1224181-A1 | SUBSTITUTED PYRROLES AS ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001027106-A1 | SUBSTITUTED PYRROLES AS ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-19 | — | — | WO | disclosed |